Brain, Vol. 125, No. 11, 2491-2506,
November 2002
© 2002 Oxford University Press
Localization of major gangliosides in the PNS: implications for immune neuropathies
1 Departments of Neurology and 2 Pharmacology, Johns Hopkins Medical Institutions, Baltimore, MD, USA, 3 Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, China, 4 Department of Clinical Neuroimmunology, Guy’s Hospital, London, UK and 5 Croatian Institute for Brain Research, University of Zagreb, Zagreb, Croatia
Correspondence to: Dr Kazim Sheikh, Department of Neurology, Johns Hopkins Hospital, 600 N-Wolfe Street/509 Pathology Building, Baltimore, MD 21205, USA E-mail: ksheik{at}jhmi.edu
Antibodies targeting major gangliosides that are broadly distributed in the nervous system are sometimes associated with clinical symptoms that imply selective nerve damage. For example, anti-GD1a antibodies are associated with acute motor axonal neuropathy (AMAN), a form of Guillain–Barré syndrome that selectively affects motor nerves, despite reports that GD1a is present in human axons and myelin and is not expressed differentially in motor versus sensory roots. We used a series of high-affinity monoclonal antibodies (mAbs) against the major nervous system gangliosides GM1, GD1a, GD1b and GT1b to test whether any of them bind motor or sensory fibres differentially in rodent and human peripheral nerves. The following observations were made. (i) Some of the anti-GD1a antibodies preferentially stained motor fibres, supporting the association of human anti-GD1a antibodies with predominant motor neuropathies such as AMAN. (ii) A GD1b antibody preferentially stained the large dorsal root ganglion (DRG) neurones, in keeping with the proposed role of human anti-GD1b antibodies in sensory ataxic neuropathies. (iii) Two mAbs with broad structural cross-reactivity bound to both gangliosides and peripheral nerve proteins. (iv) Myelin was poorly stained; all clones stained axons nearly exclusively. Our findings suggest that anti-ganglioside antibody fine specificity as well as differences in ganglioside accessibility in axons and myelin influence the selectivity of injury to different fibre systems and cell types in human autoimmune neuropathies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Hu, X. Huang, C.-C. Ling, D. R. Bundle, and N.-K. V. Cheung Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody J. Immunol., November 1, 2009; 183(9): 5748 - 5755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Kaida, T. Ariga, and R. K Yu Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A review Glycobiology, July 1, 2009; 19(7): 676 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Pritchard What's new in Guillain-Barre syndrome? Postgrad. Med. J., October 1, 2008; 84(996): 532 - 538. [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. H. Lopez, G. Zhang, M. A. Bianchet, R. L. Schnaar, and K. A. Sheikh Structural requirements of anti-GD1a antibodies determine their target specificity Brain, July 1, 2008; 131(7): 1926 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tuffereau, K. Schmidt, C. Langevin, F. Lafay, G. Dechant, and M. Koltzenburg The Rabies Virus Glycoprotein Receptor p75NTR Is Not Essential for Rabies Virus Infection J. Virol., December 15, 2007; 81(24): 13622 - 13630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Lehmann, P. H. H. Lopez, G. Zhang, T. Ngyuen, J. Zhang, B. C. Kieseier, S. Mori, and K. A. Sheikh Passive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model J. Neurosci., January 3, 2007; 27(1): 27 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pritchard What's new in Guillain-Barre syndrome? Practical Neurology, August 1, 2006; 6(4): 208 - 217. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Goodfellow, T. Bowes, K. Sheikh, M. Odaka, S. K. Halstead, P. D. Humphreys, E. R. Wagner, N. Yuki, K. Furukawa, K. Furukawa, et al. Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy J. Neurosci., February 16, 2005; 25(7): 1620 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zhang, P. H. H. Lopez, C. Y. Li, N. R. Mehta, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies Brain, May 1, 2004; 127(5): 1085 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaida, S. Kusunoki, K. Kamakura, K. Motoyoshi, and I. Kanazawa GalNAc-GD1a in human peripheral nerve: Target sites of anti-ganglioside antibody Neurology, August 26, 2003; 61(4): 465 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A De Sandre-Giovannoli, M Chaouch, I Boccaccio, R Bernard, V Delague, D Grid, J M Vallat, N Levy, and A Megarbane Phenotypic and genetic exploration of severe demyelinating and secondary axonal neuropathies resulting from GDAP1 nonsense and splicing mutations J. Med. Genet., July 1, 2003; 40(7): e87 - 87. [Full Text] [PDF]
|
|